Meeting
2021 ASCO Annual Meeting
Role of 21- gene recurrence score in patients age ≥70 with T1N0 ER/PR+ HER2- breast cancer treated with breast-conserving surgery and endocrine therapy.
Authors
Neil Chandrabhan Chevli
The University of Texas Medical Branch, Department of Radiation Oncology, Galveston, TX
Neil Chandrabhan Chevli , Waqar Haque , Kevin Thomas Tran , Andrew M. Farach , Mary R. Schwartz , Charles E. Geyer Jr., Sandra S. Hatch , E. Brian Butler , Bin S. Teh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 571)
DOI
10.1200/JCO.2021.39.15_suppl.571
Abstract #
571
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Wendy R. Parulekar
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2024 ASCO Annual Meeting
Identification of patients with DCIS with low-risk clinicopathology who benefit from radiation therapy with and without endocrine therapy after breast-conserving surgery assessed with the 7-gene biosignature.
First Author: Pat W. Whitworth
Poster
2024 ASCO Annual Meeting
Predicting epirubicin response in Danish patients with breast cancer.
First Author: Ida Kappel Buhl